Research Publications

Mahul Amin, MD

Srigley JR, Amin MB, Bostwick DG, Grignon DJ, Hammond EH, for Members of the Cancer Committee, College of American Pathologists. (2000) Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. Arch Pathol Lab Med. 124:1034-1039.

Epstein JI, Allsbrook WC, Amin MB, Egevad LL & the ISUP Grading Committee. (2005) The 2005 International Society of Urologic Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J SurgPathol. 29:1228-42.

Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH, Marshall FF, Wallace DC. (2005) mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA. 102:719-24.PMCID: PMC545582

Paner GP, Ro JY, Datta MW, Venkataraman G, Wojcik EM, Amin MB. (2007) Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol. 31:1420-9.

Chang SS, Amin MB. (2008) Utilizing the TNM staging for prostate cancer: The Sixth Edition, 2002. CA Cancer J Clin. 58:54-59.

Paner GP, Luthringer D, Amin MB. (2008) Best practices in immunohistochemistry. Prostate carcinoma and its mimics in prostate needle biopsy. Arch Pathol Lab Med. 132:1388-96.

Sung SY, Hseh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PA, Marshall FF, Chung LW. (2008) Coevolution of prostate cancer and bone stroma in 3 dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 68:9996-10003. PMCID: PMC3105756

Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI, Grignon DJ, McKiernan JM, Montironi R, Renshaw AA, Reuter VE, Wheeler TM; Members of the Cancer Committee, College of American Pathologists. (2009) Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med. 133:1568-76.

Tewari A, Patel N, Yadav R, Vaughan ED, El-Douaihy Y, Tu JJ, Amin MB, Akhtar M, Leung RA, Burns M, Kreaden U, Rubin MA, Takenaka A, Shevchuk MM. (2010) Anatomical retro-apical technique of synchronous (posterior and anterior) urethral transection: a novel approach for ameliorating apical margin positivity during robotic radical prostatectomy. BJU Int. 106:1364-73.

van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B. (2011) The ISUP Prostate Cancer Group.International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens.Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 24:16-25.

Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. (2011) Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 365:107-18.

Fine SW, Amin MB, Berney DM, Bjartell A, Egevad L, Epstein JI, Humphrey PA, Magi-Galluzzi C, Montironi R, Stief C. (2012)A Contemporary Update on Pathology Reporting for Prostate Cancer: Biopsy and Radical Prostatectomy Specimens. Eur Urol. 62:20-39.

Goodman M, Ward KC, Osunkoya AO, Datta MW, Luthringer DJ, Young AN, Marks K, Cohen V, Kennedy JC, Haber MJ, Amin MB. (2012) Frequency and determinants of discordance in Gleason score for prostate cancer: a population registry-based study. Prostate. 72(13): 1389-98. PMCID: PMC3339279

Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin D, Nelson J. Rubin M, Amin MB, van der Kwast T, Epstein JI. (2013) Contemporary Grading for Prostate Cancer: Implications for Clinical Practice. European Urol. 63:892-901.

Paner GP, Annaiah C, Gulmann C, Rao P, Ro JY, Hansel DE, Shen SS, Lopez-Beltran A, Aron M, Luthringer DJ, De Peralta-Venturina M, Cho Y, Amin MB. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum Pathol. 2014, 45(7):1473-82. PMID: 24780825.

Neil Bhowmick, PhD

Bhowmick NA*, Ghiassi M, Brown K, Singh V, Aakre M, Moses HL. (2003) TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. PNAS USA, 100(26): 15548-15553. PMID: 14657354, PMCID: PMC307605 *corresponding author

Bhowmick NA, Chytil A, Plieth D, Gorska AG, Dumont N, Shappell S, Washington, MK, Neilson EG, Moses HL. (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science, 303(5659): 848-851. PMID: 14764882

Bhowmick NA, Neilson EG, Moses HL. (2004) Stromal fibroblasts in cancer initiation and progression. Nature, 432(7015): 332-337. PMID: 15549095, PMCID: PMC3050735

Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson EG, Hayward SW, Bhowmick NA. (2008) TGF-ß responsiveness modulates paracrine prostatic sensitivity to androgen ablation. Cancer Res. 68(12): 4709-4718. PMID: 18559517, PMCID: PMC2811537

Li X, Martinez-Ferrer M, Botta V, Uwamariya C, Banerjee J, Bhowmick NA. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. (2010) Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene. 30(2): 167-177. PMCID: PMC3021901

Blum DL, Koyama T, M’Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA, Clark PE, Bhowmick NA (2008) Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin. Cancer Res. 14(23): 7790-7797. PMID: 19047106, PMCID: PMC3050736

Kiskowski MA, Jackson RS 2nd, Banerjee J, Li X, Kang M, Iturregui JM, Franco OE, Hayward SW, Bhowmick NA. (2011) Role for stromal heterogeneity in prostate tumorigenesis. Cancer Res. 71(10): 3459-3470. PMCID: PMC3096737

Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS 2nd, Revelo MP, Bhowmick NA, Hayward SW. (2011) Altered TGF-β signaling in a subpopulation of human stromal cells promotes  prostatic carcinogenesis. Cancer Res. 71(4): 1272-1281. PMCID: PMC3076790

Li X, Sterling JA, Fan KH, Vessella RL, Shyr Y, Hayward SW, Matrisian LM, Bhowmick NA. (2012)
Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol Cancer Res. 10(4): 494-503. PMID: 22290877

Jackson RS 2nd, Placzek W, Fernandez A, Ziaee S, Chu CY, Wei J, Stebbins J, Kitada S, Fritz G, Reed JC, Chung LW, Pellecchia M, Bhowmick NA. (2012) Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia. 14(7): 656-665. PMCID: PMC3421961

Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D'Souza-Schorey C, Freeman MR. (2012) Large oncosomes in human prostate cancer tissues and in the circulation of

Bhowmick NA (2012) Metastatic ability: adapting to a tissue site unseen. Cancer Cell. 22(5): 563-4.
PMID: 23153528

Qi J, Tripathi M, Mishra R, Sahgal N, Lockstone H, Ettinger S, Placzek W, Claps G, Chung LWK, Bowtell D, Gleave M, Bhowmick NA, Ronai ZA. (2012) The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell. 23(3): 332-346. PMCID: PMC3750989

Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, Wu B, Mitra S, Billet S, Fernandez A, Bhowmick NA, Kitada S, Pasquale EB, Fisher PB, Pellecchia M. (2013) Targeted delivery of paclitaxel to EphA2- expressing cancer cells. Clin Cancer Res. 19(1): 128-137. PMID: 23155185

Banerjee J, Mishra R, Li X, Jackson RS2nd , Sharma A, Bhowmick NA (2013) A reciprocal role of prostate cancer on stromal DNA damage. Oncogene. In Press. PMID: 24141771

Leland Chung, PhD

Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhau HYE, von Eschenbach AC, Chung LWK. (1990) Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. PNAS USA. 87(1): 75-79. PMCID:PMC53202

Gleave ME, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK. (1991) Acceleration of human prostate cancer growth in vivo by prostate and bone fibroblasts. Cancer Res. 51: 3753-3761.

Thalmann GN, Anezinis PE, Chang S-M, Zhau HYE, Kim E, Hopwood VL, Pathak S, von Eschenbach AE, Chung LWK. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54: 2577-2581.

Zhau HYE, Chang S-M, Chen B-Q, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK. (1996) Androgen-repressed phenotype in human prostate cancer. PNAS USA. 93: 15152-15157. PMCID:PMC26372

Odero-Marah VA, Wang R, Chu G, Xu J, Shi C, Marshall FF, Zhau HYE, Chung LWK. (2008) Receptor activator of NF-κB ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res. 18(8): 858-70.

Sung SY, Hsieh CL, Law A, Zhau HYE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PA, Marshall FF, Chung LWK. (2008) Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 68(23): 9996-10003. PMCID:PMC3105756

Yang X, Shi C, Tong R, Qian W, Zhau HYE, Wang R, Zhu G, Cheng J, Yang VW, Cheng T, Henary M, Strekowski L, Chung LWK. (2010) Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res. 16(10): 2833-2844. PMCID: PMC2871283

Huang WC, Zhau HYE, Chung LWK. (2010) Androgen receptor survival signaling is blocked by anti- β2-microglobulin monoclonal antibody via a mitogen-activated protein kinase/lipogenic pathway in human prostate cancer cells. J of Biol Chem. 285(11): 7947-56. PMCID: PMC2832945

Josson S, Nomura T, Lin JT, Huang WC, Wu D, Zhau HYE, Zayzafoon M, Weizmann MN, Gururajan M, Chung LWK. (2011) Beta2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res. 71(7): 2600-2610. PMCID:PMC3182156

Jackson RS 2nd, Placzek W, Fernandez A, Ziaee S, Chu CY, Wei J, Stebbins J, Kitada S, Fritz G, Reed JC, Chung LWK, Pellecchia M, Bhowmick NA. (2012) Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia. 14(7):656-65. PMCID: PMC3421961

Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LWK, Bowtell D, Gleave M, Bhowmick N, Ronai ZA. (2013) The E3 ubiquitin ligase Siah2 contributes to castrationresistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell. 23(3):
332-46. PMCID: PMC3750989

Zhao L, Lu YT, Li F, Wu K, Hou S, Yu J, Shen Q, Wu D, Song M, Ouyang WH, Luo Z, Lee T, Fang X, Shao C, Xu X, Garcia MA, *Chung LWK, Rettig M, Tseng HR, Posadas EM. (2013) High-Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber-Embedded Microchip for Whole Exome Sequencing. Adv Mater. Mar 26. (corresponding author) NIHMSID: 499332

Chu G C-Y, Zhau HYE, Wang R, Rogatko A, Feng X, Zayafoon M, Liu Y, Farach-Carson MC, You S,
Kim J, Freeman MR, Chung LWK. (2014) RANK- and c-Met-mediated signal network amplification promotes prostate cancer metastatic colonization. Endocrine-Related Cancer, 21(2):311-26. PMID: 24478054,PMCID: PMC3959765

Josson S, Gururajan M, Hu P, Shao C, Chu GC, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW. miR-409-3p/-5p PromotesTumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer. Clin Cancer Res. 2014, 20(17):4636-46. PMID: 24963047, PMCID: PMC4155061.

Wu JB, Shao C, Li X, Li Q, Hu P, Shi C, Li Y, Chen YT, Yin F, Liao CP, Stiles BL, Zhau HE, Shih JC, Chung LW. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J Clin Invest. 2014, 124(7):2891-908. PMID: 24865426, PMCID: PMC4071401.

Dolores Di Vizio, MD PhD

Di Vizio D, Cito L, Boccia A, Chieffi P, Insabato L, Pettinato G, Motti ML, Schepis F, D’Amico W, Fabiani, F, Tavernise B, Venuta, S, Fusco, A, Viglietto G. (2005) Loss of expression of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasia (ITGCN) to invasive germ cell tumors. Oncogene. 24(11): 1882-94. PMCID: PMC15674339

Byers RJ, Di Vizio D, O’Connell F, Tholouli E, Levenson RM, Gossard K, Twomey D, Yang Y, Benedettini E, Rose J, Ligon KL, Finn SP, Golub TR, Loda M. (2007) Semiautomated multiplex quantum dot-based in situ hybridization and spectral deconvolution. J Mol Diagn. 9: 20-29. PMCID: PMC2248801

Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K, Solomon KR, Freeman MR. (2007) Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 67(13): 6238-46. PMCID: PMC17616681

Di Vizio D, Sotgia F, Williams TM, Hassan GS, Capozza F, Frank PG, Pestell RG, Loda M, Freeman MR, Lisanti MP. (2007) Caveolin-1 is required for upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther. 6(8): 1263-8. PMCID: PMC17786030

Di Vizio D, Adam RM, Kim J, Kim R, Sotgia F, Williams T, Demichelis F, Solomon KR, Loda M, Rubin MA, Lisanti MP, Freeman MR. (2008) Caveolin-1 interacts with a lipid-raft associated population of fatty acid synthase. Cell Cycle. 7 (14): 2257-67. PMCID: PMC18635971

Di Vizio D, Solomon KR, Freeman MR. (2008) Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori. 94: 633-39. PMCID: PMC19112935

Di Vizio D, Demichelis F, Simonetti S, Pettinato G, Terracciano L, Tornillo L, Freeman MR, Insabato L.
(2008) Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal
stromal tumors. BMC Cancer. 8: 134. PMCID: PMC2396636

Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue C, True L, Demichelis F, Rubin MA, Adam RM, Beroukhim R, Freeman MR. (2009) Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69 (13): 5601-9. PMCID: PMC2853876

Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. (2009) An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease spread and epithelial Akt activation. Cell Cycle. 8(15): 2420-4. PMCID: PMC2927821

Hager MH, Morley S, Bielenberg D, Gao S, Morello M, Holcomb IN, Liu W, Mouneimne G, Kim J,
Adam RM, Demichelis F, Isaacs WB, Higgs HN, Vessella RL, Di Vizio D, Freeman MR. (2012) DIAPH3 governs the cellular transition to the amoeboid phenotype. EMBO Molecular Medicine. 4(8):743-60 PMID: 22593025 PMC Journal – In Process

Di Vizio D, Morello M, Dudley A, Schow P, Adam R, Morley S, Mulholland D, Hager M, Insabato L, Moses M, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin M, D'Souza-Schorey C, Freeman MR. (2012) Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. American Journal Pathology. 181(5): 1573-84. PMCID: PMC3483805

Mukhopadhyay NK, Kim J, You S, Morello M, Hager MH, Huang W, Ramachandran A, Yang J, Cinar B, Rubin MA, Adam RM, Oesterreich S, Di Vizio D, Freeman MR. (2013) Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2. Oncogene. [Epub ahead of print] PMCID: PMC23893242

Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, Bartolucci G, Danza G, Adam RM, Thompson TC, Lisanti MP, Freeman MR, Di Vizio D. (2013) Loss of Caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumor progression. Journal of Pathology. 231(1):77-87. PMCID: PMC23729330

Israelsen WJ, Dayton TL, Fiske BP, Hosios A, Bellinger G, Li J, Yu J, Sasaki M, Horner JW, Burga LN, Xie J, DePinho RA, Jacks T, Wulf GM, Di Vizio D, Mills G, Cantley LC, Vander Heiden MG. (2013) PKM2 deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell. 155(2):397- 409. PMCID: PMC24120138

Morello M, Minciacchi VR, de Candia P, Yang J, Posadas E, Kim H, Griffiths D, Bhowmick NA, Chung LW, Gandellini P, Freeman MR, Demichelis F, Di Vizio D. (2013) Large oncosomes: MicroRNA profiling and identification in the circulation of patients with metastases. Cell Cycle. 12(22). [Epub ahead of print]. PMCID: PMC24091630

Robert Figlin, MD FACS

Deng, J., Liu, Y., Lee, H., Hermann, A., Zhang, W., Zhang, C., Shen, S., Priceman,S., Kujawski, M., Pal, S., Raubitschek, A., Hoon, D.S., Forman, S., Figlin, R., Jove, R., Yu, H., S1PR1-STAT3 Signaling is Crucial for Myeloid Cell Colonization at Future Metastatic Sites. Cancer Cell May 25;25:21(5), 642-54, 2012. PMID:22624714.

Motzer, R.J., Hutson, T.E., Olsen, M.R., Hudes, G.R., Burke, J.M., Edenfield, W.J., Wilding, G., Agarwal, N., Thompson, J.A., Cella, D., Bello, A., Korytowsky, B., Yuan, J., Valota, O., Martell, B., Hariharan, S., Figlin, R.A., Randomized Phase II Trial of Sunitinib on an Internittent versus Continuous Dosing Schedule as First-Line Therapy of Advanced Renal Cell Carcinoma,  J Clin Oncol. Apr 20; 30(12):1371-7, 2012.

Figlin, R.A., Sternberg, C., Wood, C., Novel Agents and Approaches for Advanced Renal Cell Carcinoma, J Urol Sept; 188 (3):707-15, 2012. PMID: 22818130.

Posadas, E.M., Figlin, R.A., Understanding the Role of MET Kinase in Cancer Therapy, J Clin Oncol. Jan 10; 31 (2): 169-170, 2013, PMID: 23213104.
5.Figlin, R.A., Kaufmann, I., Brechbiel, J., Targeting PI3K and mTORC2 in Metastatic Renal Cell Carcinoma: New Strategies for Overcoming Resistance to VEGFR and mTORC2 Inhibitors: Int J Cancer 2013 Aug 15;133(4):788-96. PMID: 23319457.

Pal, S., Figlin R.A., Unraveling the Role of Hypoxia Inducible Factor (HIF) in Renal Cell Carcinoma: A Biologic and Therapeutic Perspective, Cancer Discovery, 1(3); 198-9, 2011.

Xin, H., Hermann, A., Reckamp, K., Zhang, W., Pal,S., Hedvat, M., Zhang, C.., Liang, W., Scuto, A., Weng, S., Morosini, D., Cao, Z.A., Zinda, M., Figlin, R.A, Huszar, D., Jove, R., Yu, H., Anti-angiogenic and Ani-metatstatic Activity of JAK Inhibitor AZD 1480, Cancer Res, 2011 Sept 15 [Epub ahead of print].

Hutson, T.E., Davis, I.D., Machiels, J.P., deSouza, P.L., Rottey, S., Hong, B.F., Epstein, R., Baker, K.L., McCann, L., Crofts, T., Liu, Y., Pandite, L., Figlin, R.A., Efficacy and Safety of Pazopanib in Patients with Metastatic Renal Cell Carcinoma, J Clin Oncol. Jan 20; 28(3):475-80, 2010.

Hermann, A., Kortylewski, M., Kujawski, M., Zhang, C., Reckamp, K.L., Armstrong, B., Wang,L., Kowolik, C.M., Deng, J., Figlin, R.A, Yu. H., Targeting Stat3 in the Myeloid Compartment Drastically Improves Adoptively Transferred T Cell Antitumor Functions in vivo. Cancer Res, 70 (19); 7455-64, 2010.

Pal, S.K., Kortylewski, M., Yu, H., Figlin, R.A., Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of Biomarkers, Mol Cancer Ther, Dec 9(12):3115-25, 2010.

Motzer, RJ, Hutson, TE, Tomczak, P, Michaelson, MD, Bukowski, RM, Oudard, S., Negrier, S, Szczylik, C, Pili, R, Bjarnason, GA, Garcia del Muro, X, Sosman, JA, Solska, E, Wilding, G, Thompson, JA, Kim, ST, Chen, I, Huang, X, Figlin, RA, Overall Survival and Updated Results for Sunitinib Versus Interferon Alfa in Patients with Metastatic Renal Cell Carcinoma, J Clin Oncol, 1:27(22):3484-3490, Aug 2009.

Weiner, LM, Belldegrun, A, Crawford, J, Tolcher, TW, Lockbaum, P, Arends, R, Navale, L, Amado, R, Schwab, G, Figlin, RA, Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies, Clin Cancer Res, 15:14(2):502-508, Jan 2008.

Weiner, L.M., Belldegrun, A., Crawford, J., Tolcher, T.W.,Lockbaum, P., Arends, R., Navale, L., Amado, R., Schwab, G., Figlin, R.A., Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies, Clin Cancer Res, Jan 15;14(2):502-8, 2008.

Lam, JS, Pantuck, AJ, Belldegrun, AS, Figlin, RA, Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis and Patient Selection for Clinical Trials, Clin Cancer Res, 13(2):703s-708s, 2007.

Motzer, RJ, Hutson, TE, Tomczak, P, Michaelson, MD, Bukowski, RM, Rixe, O, Oudard, S, Negrier, S, Szczylik, C, Kim, ST, Chen, I, Baum, CM, Figlin, RA, Phase III Randomized Trial of Sunitinib Malate Versus Interferon-alfa as First Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma, N Engl J Med, 356(2):115-124, 2007.

Michael Freeman, PhD

Freeman MR, Schneck FX, Gagnon M, Corless C, Soker S, Niknejad K, Peoples GE, Klagsbrun M. (1995) Peripheral blood T lymphocytes and T cells infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res. 55:4140-4145. PMID: 7545086 377 citations

Lin J, Adam RM, Santiestevan E, Freeman MR. (1999) The phosphatidylinositol 3’-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res. 59:2891-2897. PMID: 10383151 262 citations

Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 115:959-968. PMID: 15776112, PMCID: PMC1064980 250 citations

Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K, Solomon KR, Freeman MR. (2007) Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 67:6238-6246. Selected as a Highlight of the issue. PMID: 17616681

Kim J, Jahng WJ, Di Vizio D, Lee JS, Jhaveri R, Rubin MA, Shisheva A, Freeman MR. (2007) The phosphoinositide kinase PIKfyve mediates EGF receptor trafficking to the nucleus. Cancer Res. 67:9229-9237. PMID: 17909029

Cinar B, Fang PK, Lutchman M, Di Vizio D, Adam RM, Pavlova N, Rubin MA, Yelick P, Freeman MR. (2007) The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt. EMBO J. 26:4523-4534. PMID: 1793290

Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, True L, Rubin MA, Adam RM,
Beroukhim R, Demichelis F, Freeman MR. (2009) Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69:5601-5609. PMID: 19549916, PMCID: PMC2853876

Yang W, Di Vizio D, Kirchner M, Steen H, Freeman MR. (2010) Proteome-scale characterization of
human S-acylated proteins in lipid raft-enriched and non-raft membranes. Mol Cell Proteomics. 9:54-
70. PMID: 19801377, PMCID: PMC2808267

Freeman MR, Di Vizio D, Solomon KR. (2010) The Rafts of the Medusa: cholesterol targeting in cancer therapy. Oncogene. 29:3745-3747. PMID: 20440260

Wu X, Gao H, Ke W, Hager M, Xiao S, Freeman MR, Zhu Z. (2011) VentX trans-activates p53 and p16ink4a to regulate cellular senescence. J Biol Chem. 286:12693-12701. PMID: 21325273, PMCID: PMC3069469

Yang W, Chung YG, Kim Y, Kim TK, Keay SK, Zhang CO, Ji M, Hwang D, Kim KP, Steen H, Freeman MR, Kim J. (2011) Quantitative proteomics identifies a b-catenin network as an element of the signaling response to Frizzled-8 protein-related antiproliferative factor. Mol Cell Proteomics. 10:M110.007492. PMID: 21422242, PMCID: PMC3108841

Cinar B, Kisaayak-Collak F, Lopez D, Akgul S, Mukhophadyay NK, Kilicarslan M, Gioeli D, Freeman MR. (2011) MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling. Cancer Res. 71:4303-4313. PMID: 21512132, PMCID: PMC3117069

Hager MH, Morley S, Bielenberg DR, Gao S, Matteo M, Holcomb IN, Liu W, Mouneimne G, Demichelis F, Kim J, Solomon KR, Adam RM, Isaacs WB, Higgs HN, Vessella RL, Di Vizio D, Freeman MR. (2012) DIAPH3 governs the cellular transition to the amoeboid tumor phenotype. EMBO Mol Med. 4:743-760. PMID: 22593025, PMCID: PMC3494074

Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D’Souza-Schorey C, Freeman MR. (2012) Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 181:1573-1584. (Selected as a Highlight of the issue. Cover art). PMID: 23022210, PMCID: PMC3483805

Mukhopadhyay M, Kim J, You S, Morello M, Hager MH, Huang WC, Ramachandran A, Yang J, Cinar B, Rubin MA, Oesterreich S, Di Vizio D, Freeman MR. (2014) Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2. Oncogene. 33(25):3235-45, PMID: 23893242

Hyung Kim, MD

Kim, H.L., Griend Vander, D. J., Yang, X., Benson, D.A., Dubauskas, Z., Yoshida, B.A., Chekmareva, M.A., Ichikawa, Y., Sokoloff, M.H., Zhan, P., Karrison, T., Lin, A., Stadler, W. M., Ichikawa, T., Rubin, M.A., Rinker-Schaeffer, C.W., Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.  Cancer Research. 2001; 61: 2833-2837.   [PMID: 11306453]

Kim, H.L., Seligson, D., Liu, X., Janzen, N., Bui, M., Yu, H., Tao, S., Figlin, R.A., Horvath, S., Belldegrun, A.S.,  Using protein expressions to predict survival in clear cell renal carcinoma.  Clinical Cancer Research, 2004; 10: 5464-5471  [PMID: 15328185]

Kim, H.L., Seligson, D., Liu, X., Janzen, N., Bui, M., Yu, H., Tao, S., Figlin, R.A., Horvath, S., Belldegrun, A.S., Using tumor markers to predict the survival of patients with metastatic renal cell carcainoma. J Urol, 2005; 173(5): 1496-1501. [PMID: 15821467]

Yang, X., Tan, M. H., Kim, H.L., Ditlev, J.A., Betten, M.W., Png, C.E., Kort, E.J., Futami, K., Furge, K.A., Takahashi, M., Kanayama, H.O., Tan, P.H., Teh, B.X., Luan, C., Wang, K., Pins, M., Tretiakova, M.S., Anema, J.G., Kahnoski, R.J., Nicol, T.L., Stadler, W.M., Vogelzang, N. J., Amato, R., Seligson, D., Figlin, R.A., Belldegrun, A.S., Rogers, C.G., Ten, B., The A molecular classification of papillary renal cell carcinoma. Cancer Research, 2005; 65(13):5628-5637.   [PMID: 15994935]

Glenn, S.T., Jones, C.A., Liang, P., Kaushik, D., Gross, K. W., Kim, H.L.,  Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers.  BioTechniques 2007 November; 43(5):639-647.  [PMID: 18072593]

Kim, H.L., Sun, X., Subjeck, J.R., XY, W.,  Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.  Cancer Immunol Immunother 2007 July;56(7):1097-105. [PMID: 18072593]

Wang, Y., Wang, X.Y., Subjeck, J., Kim, H.L.,  Carbonic Anhydrase IX has Chaperone-like Functions and is an Immunoadjuvant. Molecular Cancer Therapeutics, 2008 December; 7(12):3867-3877. [PMCID: 2676339]

Kim, H.L., Shah, S.K., Tan, W., Shikanov, S.A., Zorn, K.C., Shalhav, A.L., Wilding, G.E.,  Estimation and Prediction of Renal Function in Patients with Renal Tumor. J Urol 2009 Apr; 181(6): 2451-60.  [PMID: 19371883]

Yi, H., Yu, X., Gao, P., Wang, Y., Kim, H.L., Subjeck, J.R., and Wang, X.Y., Pattern recognition scavenger receptor SRA/CD204 down-regulates TLR4 signaling dependent CD8 T-cell activation.  Blood 2009 Jun 4;113(23):5819-28.   [PMCID: 2700321]

Hellenthal, N.J., Underwood, W., Penetrante, R., Litwin, A., Zhang, S., Wilding, G., Teh, B.T., Kim, H.L., Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urology, 2010 Sept, 184(3):859-64.  [PMCID: 3105599 ]

Glenn, S.T., Head, KL., Teh, B.T., Gross, K.W., Kim, H.L., Maximizing RNA yield from archival renal tumors and optimizing gene expression analysis. J Biomol Screen 2010 Jan 15(1):80-5.  [PMCID: 2902272]

Wang, Y., Wang, X.Y., Subjeck, J.R., Shrikant, P.A., Kim, H.L., Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer, 2011 Feb, 104(4):643-52 [PMCID: 3049595]

Zhang, H., Berel, D., Wang, Y., Figlin, R.A., Kim, H.L., A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.  Plos One. 2013 Jan; 8(1):e54918 [PMC3551765]

Li, P., Grigorenko, E., Funari, V., Enright, E., Zhang, H., Kim, H.L., Evaluation of a high-throughput, microfluidics platform for performing Taqman™ qPCR using formalin-fixed paraffin embedded tumors.  Bioanalysis. 2013 July: 5(13): 1623-1633 [PMC523148]

Wang, Y., Sparwasser, T., Figlin, R., Kim, H.L. Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Research. 2014 April: 74:2217-2228 [PMID: 24574514]  

Jayoung Kim, PhD

Kim J, Adam RM, Freeman MR. (2002) Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Research. 62(5): 1549-1554. PMID: 11888934

Kim J, Adam RM, Solomon KR, Freeman MR. (2004) Involvement of cholesterol-rich lipid rafts in
interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology.
145(2): 613-619. PMID: 14563701

Kim J, Lin J, Adam RM, Lamb C, Shively SB, Freeman MR. (2005) An oxidative stress mechanism mediates chelerythrine-induced heparin-binding EGF-like growth factor ectodomain shedding. Journal of Cellular Biochemistry. 94(1): 39-49. PMID: 15490481

Zhuang L, Kim J*, Adam RM, Solomon KR, Freeman MR. (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. Journal of Clinical Investigation. 115(4): 959-968. *co-first author, PMID: 15776112 PMCID:PMC1064980

Kim J, Jahng WJ, Di Vizio D, Lee JS, Jhaveri R, Rubin MA, Shisheva A. Freeman MR. (2007) The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. Cancer Research. 67(19): 9229-9237. PMID: 17909029

Di Vizio D, Adam RM, Kim J, Kim R, Sotgia F, Williams T, Demichelis F, Solomon KR, Loda M, Rubin
MA, Lisanti MP, Freeman MR. (2008) Caveolin-1 interacts with a lipid raft-associated population of fatty
acid synthase. Cell Cycle. 7(14): 2257-2267. PMID: 18635971

Solomon KR, Pelton K, Boucher K, Joo J, Tully C, Zurakowski D, Schaffner CP, Kim J, Freeman MR.
(2009) Ezetimibe is an inhibitor of tumor angiogenesis. American Journal of Pathology. 174(3): 1017-
1026. PMID: 19179610, PMCID:PMC2665761

Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, True L, Rubin MA, Adam RM,
Beroukhim R, Demichelis F, Freeman MR. (2009) Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Research. 69(13): 5601-5609. PMID: 19549916, PMCID:PMC2853876

Yang W, Chung YG, Kim Y, Kim TK, Keay SK, Zhang CO, Ji M, Hwang D, Kim KP, Steen H, Freeman MR, Kim J*. (2011) Quantitative proteomics identifies a β-catenin network as an element of the signaling response to antiproliferative factor in interstitial cystitis. Molecular Cellular Proteomics. 10(6): M110.007492. PMID: 21422242, PMCID:PMC3108841 *corresponding author

Kim J*, Kim W, Loda MF, Freeman MR. (2012) Ubiquitin specific protease, USP2a, enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle. 11(6): 1123-30. PMID: 22370483, PMCID:PMC3335918 *corresponding author

Hager MH, Morley S, Bielenberg DR, Gao S, Morello M, Holcomb IN, Liu W, Mouneimne G, Demichelis F, Kim J, Solomon KR, Adam RM, Isaacs WB, Higgs HN, Vessella RL, Di Vizio D, Freeman MR. (2012) DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Molecular and Medicine. 4(8): 743-60. PMID: 22593025, PMCID:PMC3494074

Kim J*, Di Vizio D, Kim T, Kim J, Kim M, Pelton K, Hwang D, Solomon KR, Freeman MR. (2012) The response of the prostate to changes in circulating cholesterol: activating transcription factor 3 (ATF3) as a cholesterol sensor. PLoS ONE. 7(7): e39448. PMID: 22768301, PMCID:PMC3388073 *cocorresponding author

Yang W, Kim Y, Kim T, Keay SK, Kim KP, Steen H, Freeman MR, Hwang D, Kim J*. (2012) Integration
analysis of quantitative proteomics and transcriptomics data identifies potential targets of frizzled-8 protein-related antiproliferative factor in vivo. British Journal of Urology International. 110(11c): E1138-E1146. PMID: 22738385, PMCID:PMC3451241 *corresponding author

Kim J*, Keay SK, You S, Loda M, Freeman MR. (2012) A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2. PLoS ONE. 7(12): e50392.
PMID: 23236372, PMCID:PMC3516501 *corresponding author

Kim J, Morley S, Le M, Bedoret D, Umetsu DT, Di Vizio D, Freeman MR. (2014) Enhanced Shedding of Extracellular Vesicles from Amoeboid Prostate Cancer Cells: Potential Effects on the Tumor Microenvironment, Cancer Biology & Therapy, 14;15(4). PMID: 24423651

Beatrice Knudsen, MD PhD

Akfirat C, Zhang X, Ventura A, Berel D, Colangelo ME, Miranti CK, Krajewska M, Reed JC, Higano CS, True LD, Vessella RL, Morrissey C, Knudsen BS. (2013) Tumor Cell Survival Mechanisms in Lethal Metastatic Prostate Cancer Differ Between Bone and Soft Tissue Metastases. The Journal of Pathology, Feb 18. DOI: 10.1002/path.4180. PMID: 23420560

FitzGerald LM, Zhang X, Kolb S, Kwon EM, Liew YC, Hurtado-Coll A, Knudsen BS, Ostrander EA, Stanford JL. (2012) Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Human Mutation, Aug 7. doi: 10.1002/humu.22176. PMID:22887727 PMCID: PMC3532957

Yan D, Wang P, Linden M, Knudsen BS, Randolph T. (2012) Statistical methods for tissue array images - algorithmic scoring and co-training. The Annals of Applied Statistics, 6{3): 1280-1305. PMID:22984376, PMCID: PMC3441061

Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Çeliktaş M, Hwang MS, Darling DS, Coleman I, Nelson PS, Nguyen HM5, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS. (2011) Metastatic progression of prostate cancer and E-cadherin: regulation by ZEB1 and SRC family kinases. Am J Pathol 179(1):400-10. PMID: 21703419, PMCID: PMC3123858

Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, Lemeur N, Gentleman RC, True LD,
Nelson PS, Lin DW. (2010) Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect. Clin Cancer Res.
16(22):5414-23. PMID: 20935156, PMCID: PMC2992073

Ventura AP, Radhakrishnan S, Green A, Rajaram SK, Allen AN, O'Briant K, Schummer M, Karlan B, Urban N, Tewari M, Drescher C, Knudsen BS. (2010) Activation of the MEK - S6 pathway in highgrade ovarian cancers. Applied Immunohistochemistry & Molecular Morphology, 18(6): 499-508. PMID: 20661131, PMCID: PMC2989426

Lamb LE, Knudsen BS, Miranti CK. (2010) E-cadherin-mediated survival of androgen-receptorexpressing secretory prostate epithelial cells derived from a stratified in vitro differentiation model. J. Cell Sci. 123(Pt 2):266-76. PMID: 20048343

Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O’Briant KC, Ventura AP, Godwin AK,
Karlan BY, Drescher CW, Urban N, Knudsen BS, Tewari M. (2010) Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-toepithelial transition. Gynecol Oncol. 116(1):117-25. PMID: 19854497, PMCID: PMC2867670

Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, Xie Q, Hay R, Vande Woude G, Cao B. (2009) A novel multipurpose monoclonal antibody for evaluating human c-MET expression in preclinical and clinical settings. Applied Immunohistochemistry & Molecular Morphology. 17(1):57-67. PMID: 18815565, PMCID: PMC2952101

Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M. (2009) Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One. 4(4):e5311 PMID: 19390579, PMCID: PMC2668797

Lutz BR, Dentinger CE, Nguyen LN, Sun L, Zhang J, Allen AN, Chan S, Knudsen BS. (2008) Spectral analysis of multiplex Raman probe signatures. ACS Nano, 2(11):2306-14. PMID: 19206397, PMCID: PMC2662378

Lutz BR, Dentinger C, Sun L, Nguyen L, Zhang J, Chmura AJ, Allen A, Chan S, Knudsen BS. (2008) Raman nanoparticle probes for antibody-based protein detection in tissues. J Histochem Cytochem. 56(4):371-9. PMID: 18071064, PMCID: PMC2326103

Knudsen BS, Allen AN, McLerran DF, Vessella RL, Karademos JK, Davies JE, Magsodi B, McMaster GK, Kristal AR. (2008) Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. J Mol Diagn. 10(2):169-76. PMID: 18276773, PMCID: PMC2259472

Xu C, Graf LF, Fazli L, Coleman IM, Mauldin DE, Li D, Nelson PS, Gleave M, Plymate SR, Cox ME, Torok-Storb BJ, Knudsen BS. (2007) Regulation of global gene expression in the bone marrow microenvironment by androgen: Androgen ablation increases insulin-like growth factor binding protein-5 expression. Prostate, 67(15):1621-9. PMID: 17823924

Edwin Posadas, MD FACP

Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, Posadas EM. (2013) NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods. Jun 29. pii: S1046-2023(13)00220-X. PMID: 23816790

Zhao L, Lu YT, Li F, Wu K, Hou S, Yu J, Shen Q, Wu D, Song M, Ouyang WH, Luo Z, Lee T, Fang X, Shao C, Xu X, Garcia MA, Chung LW, Rettig M, Tseng HR, Posadas EM. (2013) High-Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber-Embedded Microchip for Whole Exome Sequencing. Adv Mater. Mar 26. PMID: 23529932

Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA. (2013) A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 71(4): 883-92. PMCID: PMC3609871

Posadas EM, Figlin RA. (2013) Understanding the role of MET kinase in cancer therapy. J Clin Oncol.
31(2): 169-70. PMID: 232131045.

Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ, O'Donnell PH, Stadler WM, Posadas EM. (2012) A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 15(1): 87-92. PMID: 22006050

Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC,
Paliwal P, Agrawal S, Logothetis CJ. (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 118(1): 63-71. PMID: 21976132

Gururajan M, Posadas EM, Chung LW. (2012) Future perspectives of prostate cancer therapy. Transl Androl Urol. 1(1): 19-32. PMCID: PMC3389805

Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. (2011) Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer. Urology. 77(5): 1166-71. PMCID: PMC3394099

Jensen AR, David SY, Liao C, Dai J, Keller ET, Al-Ahmadie H, Dakin-Haché K, Usatyuk P, Sievert MF, Paner GP, Yala S, Cervantes GM, Natarajan V, Salgia R, Posadas EM. (2011) Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 17(10): 3112-22. PMID: 21364031 PMCID: PMC3118405

Saito YD, Jensen AR, Salgia R, Posadas EM. (2010) Fyn: a novel molecular target in cancer. Cancer. 116(7): 1629-37. PMCID: PMC3118405

Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabrò F, Cheng S, Trudel GC, Paliwal P, Sternberg CN. (2009) Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 15(23): 7421-8. PMCID: PMC3394097

Limvorasak S, Posadas EM. (2009) Kinase Inhibitors in Prostate Cancer. Anticancer Agents Med Chem. 9(10): 1089-14.

Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W,
Gandara DR. (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 20(3): 179-84. PMCID: PMC2741693

Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz, J, Jones E, Chen CC, Figg WD. (2008) A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Can Res. 14(1): 209-14. PMID: 18172272

Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Steinberg SM, Lee MJ, Chung EJ, Trepel JB, Kohler D, Sparreboom A, Chen C, Jones E, Figg WD, Dahut WL. (2005) A phase II study of oral perifosine in androgen-independent metastatic prostate cancer. Cancer Biol & Thera. 4(10): 1133-7. PMID: 16138006

Wen-Chin Huang, PhD

Huang, W.C., Xie, Z., Konaka, K., Sodek, J., Zhau, H.Z., and Chung, L.W. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: Role of cAMP-dependent protein kinase A signaling pathway. Cancer Res, 65: 2303-13 (2005)

Huang, W.C., Wu, D., Xie, Z., Zhau, H.E., Nomura, T., Zayzafoon, M., Pohl, J., Hsieh, C.L., Weitzmann, M.N., Farach-Carson, M.C., and Chung, L.W. 2-Microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res, 66: 9108-16 (2006)

Nomura, T., Huang, W.C., Zhau, H.E., Wu, D., Xie, Z., Mimata, H., Zayzafoon, M., Young, A.N., Marshall, F.F., Weitzmann, M.N., and Chung, L.W. 2-Microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res, 12: 7294-305 (2006)

Wu, D, Zhau, H.E., Huang, W.C., Iqbal, S. Habib, F., Sartor, O., Cvitananovic, L., Marshall, F.F., Xu, W., and Chung, L.W. cAMP-response element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene, 26: 5070-7 (2007)

Nomura, T., Huang, W.C., Seo, S., Zhau, H.E., Mimata, H., and Chung, L.W. Targeting 2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol, 178: 292-300 (2007)

Huang, W.C., Havel, J. J., Zhau, H.E., Qian, W.P., Lue, H., Chu C., Nomura, T. and Chung, L.W. 2-Microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clin Cancer Res, 14: 5341-7 (2008)

Huang, W.C., Zhau, H.E. and Chung, L.W. Androgen receptor survival signaling is blocked by anti-2-microglobulin monoclonal antibody via a mitogen-activated protein kinase/lipogenic pathway in human prostate cancer cells. J Biol Chem, 285: 7947-56 (2010)

Josson, S., Nomura, T., Lin, J., Huang, W.C., Wu, D, Zhau, H.E., Zayzafoon, M., and Chung, L.W. 2-Microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res, 71: 2600-10 (2011)

9.Shigemura, K., Huang, W.C., Li, X., Zhau, H.E., Zhu, G., Gotoh, A., Fujisawa, M., Xie, J., Marshall, F.F. and Chung,  L.W. Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancer-associated prostate stromal cells. Prostate, 71: 2600-10 (2011)

Huang, W.C., Li, X., Liu, J., Lin, J. and Chung, L.W. Activation of androgen receptor, lipogenesis and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res, 10: 133-42 (2012)

Josson, S., Matsuoka, Y., Gururajan, M., Nomura, T., Huang, W.C., Yang, X., Lin, J., Bridgman, R., Chu. C.Y., Johnston, P., Zayzafoon, M., Hu, P., Zhau, H.E., Berel, D., Rogatko, A. and Chung, L.W. Inhibition of 2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells. PLoS ONE, 8(7): e68366 (2013)

Li, X., Chen, Y.T., Josson, S., Mukhopadhyay, N.K., Kim, J., Freeman, M.R. and Huang, W.C. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer. PLoS ONE, 8(8): e70987 (2013)

Mukhopadhyay, N.K., Kim, J., You, S., Morello, M., Hager M.H., Huang, W.C., Ramachandran, A., Yang, J., Lopez. D., Cinar, B., Rubin, M.A., Adam, R.M., Oesterreich, S., Di Vizio, D. and Freeman, M.R. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2. Oncogene, 33:3235-45 (2014)  

Nomura, T., Huang, W.C., Zhau, H.E., Josson, S., Mimata, H., and Chung, L.W. 2-microglobulin-mediated signaling as a target for cancer therapy. Anticancer Agents Med Chem, 14(3): 343-52 (2014)

Li, X., Chen, Y.T., Hu, P. and Huang, W.C. Fatostatin displays high anti-tumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther, 13:855-66 (2014)

Howard Sandler, MD MS FASTRO

Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, Watkins-Bruner D, Reeve BB, Sandler HM. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst. 2014, 106(7). PMID: 25006192 (in press)

Chen RC, Hamstra DA, Sandler HM, Zietman AL. Complications of prostate cancer treatment. Lancet Oncol. 2014, 15(4):e150. PMID: 24694635.

Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil -cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013, 14(9):863-72. PMID: 23823157, PMCID: PMC3955198.

Sandler HM, Mirhadi AJ. Current role of radiation therapy for bladder cancer. Semin Oncol. 2012, 39(5):583-7. PMID: 23040254.

Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011, 306(11):1205-14. PMID: 21934053, PMCID: PMC3831607.

Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011, 365(2):107-18. PMID: 21751904.

Hsu IC, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, Speight J, Vigneault E, Ivker R, Sandler H. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys. 2010, 78(3):751-8. PMID: 20207506; PMCID: PMC2946454.

Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2010, 78(5):1314-22. PMID: 20378270; PMCID: PMC2920356.

Souhami L, Bae K, Pilepich M, Sandler H. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a  secondary analysis of Radiation Therapy Oncology Group 85-31. Int J Radiat Oncol  Biol Phys. 2010, 78(5):1301-6. PMID: 20356687.

Hamstra DA, Michalski JM, Roach M, Sandler HM. Do not count out external-beam radiation therapy for high-risk prostate cancer. J Clin Oncol. 2010, 28(28):e518-9; PMID: 20660824.

Rosenthal SA, Sandler HM. Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol. 2010, 7(1):31-8. PMID: 20062072.

Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009, 27(25):4055-61. PMID:19636019, PMCID: PMC2734419.

Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond ME, Venkatesan V, Byhardt RW, Asbell SO, Shipley WU, Sandler HM. The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02. Clin Cancer Res. 2009, 15(17):5478-84.  PMID: 19706804, PMCID: PMC2763098.

14.Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009, 27(1):92-9. PMID: 19047297, PMCID: PMC2645096.

Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM. Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J. Natl. Cancer Inst., 2009, 101(4): 228-36.

Ruoxiang Wang, MD PhD

Hu PZ, Chung LWK, Berel D, Frierson HF, Yang H, Liu CY, Wang RX, Li QL, Rogatko A, Zhau HYE. (2013) Convergent RANK- and c-Met-mediated signaling components predict survival of patients with
prostate cancer in interracial comparative study. PLoS ONE. 8(9):e73081.

Yang XJ, Shao C, Wang RX, Chu CY, Hu PZ, Master V, Osunkoya AO, Kim HL, Zhau HYE, Chung LWK. (2012) Optical imaging of kidney cancer with novel near-infrared heptamethine carbocyanine fluorescent dyes. J. Urol. 189(2): 702-710.

Wang RX*, Sun XJ, Wang CY, Hu PZ, Chu CY, Liu SR, Zhau HYE, Chung LWK. (2012)
Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression. PLoS ONE. 7(8):e42653.

Zhau HYE, He H, Wang CY, Zayzafoon M, Morrissey C, Vessella RL, Marshall FF, Chung LWK, Wang RX*. (2011) Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells. Clin. Cancer Res. 17:2159-2169.

Zhang D, He DL, Xue Y, Wang RX, Wu K, Xie H, Zeng J, Wang X, Zhau HYE, Chung LWK, Chang LS, Li L. (2011) PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res. 71:2193-2202.

Gunderson K, Wang CY, Wang RX*. (2010) Global prostate cancer incidence and the migration, settlement, and admixture history of the northern Europeans. Cancer Epidemiol. 35:320-327.

Sun XJ, He H, Xie ZH, Qian WP, Zhau HYE, Chung LWK, Marshall FF, Wang RX*. (2010) Matched pairs pairs of human prostate stromal cells display differential tropic effects on LNCaP prostate cancer cells. In Vitro Cellular & Developmental Biology – Animal. 46:538-546.

He H, Xu JC, Nelson PS, Marshall FF, Chung LWK, Zhau HYE, He DL, Wang RX*. (2010) Differential expression of the α2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells. Prostate. 70:993-1001.

Josson S, Matsuoka Y, Chung LWK, Zhau HYE, Wang RX*. (2010) Tumor stroma co-evolution in prostate cancer progression and metastasis. Semin. Cell Dev. Biol. 21:26-32.

He H, Yang XJ, Davidson AJ, Wu DQ, Marshall FF, Chung LWK, Zhau HYE, Wang RX*. (2010)
Progressive epithelial to mesenchymal transitions in ARCaPE prostate cancer cells during xenograft tumor formation and metastasis. Prostate. 70:518-528.

Yang XJ, Shi CM, Tong R, Qian W, Zhau HYE, Wang RX, Zhu G, Cheng J, Yang VW, Cheng T,
Henary M, Strekowski L, Chung LWK. (2010) Near IR heptamethine cyanine dye-mediated cancer imaging. Clin. Cancer Res. 16:2833-2844.

Zhang S, Zhau HYE, Osunkoya AO, Iqbal S, Yang X, Fan S, Chen Z, Wang RX, Marshall FF, Chung LWK, Wu D. (2010) Vascular endothelial growth factor regulated myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-Met signaling in human prostate cancer cells. Mol. Cancer. 9:9.

Josson S, Sharp S, Sung SY, Johnstone PA, Aneja R, Wang RX, Gururajan M, Turner T, Chung LWK, Yates C. (2010) Tumor-stromal interactions influence radiation sensitivity in epithelial- versus mesenchymal-like prostate cancer cells. J. Oncol. doi:pii: 232831. 10.1155/2010/232831. PMCID: PMC2926670

Xu JC, Wang RX, Xie ZH, Odero-Marah V, Pathak S, Multani A, Chung LWK, Zhau HYE. (2006)
Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate. 66:1664-1673.

Chung LWK, Huang WC, Sung SY, Wu DQ, Odero-Marah V, Nomura T, Shigemura K, Miyagi T, Seo S, Shi CH, Molitiemo J, Elmore J, Anderson C, Isotani S, Edlund M, Hsieh CL, Wang RX, Shehata B, Zhau HYE. (2006) Stromal-epithelial interaction in prostate cancer progression. Clin. Genitourin. Cancer. 5:162-170.

Wei Yang, PhD

Yang, W., Kim, Y., Kim, T. K., Keay, S. K., Kim, K. P., Steen, H., Freeman, M. R., Hwang, D., Kim, J. (2012) Integration analysis of quantitative proteomics and transcriptomics data identifies potential targets of frizzled-8 protein-related antiproliferative factor in vivo. BJU Int. 110: E1138-46. (PMC3461241)

Freeman, M. R., Yang, W., Di Vizio, D. (2012) Caveolin-1 and prostate cancer progression. Adv. Exp. Med. Biol. 729: 95-110.

Dowal, L.*, Yang, W.*, Freeman, M. R., Steen, H., Flaumenhaft, R. (2011) Proteomic analysis of palmitoylated platelet proteins. Blood 118: e62-73. (*co-first author) (PMC3186346)

Yang, W., Chung Y. G., Kim, Y., Kim, T. K., Keay, S. K., Zhang, C. O., Ji, M., Hwang, D., Kim, K. P., Steen, H., Freeman, M. R., Kim, J. (2011) Quantitative proteomics identifies a β-catenin network as an element of the signaling response to frizzled-8 protein-related antiproliferative factor. Mol. Cell. Proteomics 10: M110.007492 (PMC3108841).

Yang, W., Di Vizio, D., Kirchner, M., Steen, H., Freeman, M. R. (2010) Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and non-raft membranes. Mol. Cell. Proteomics 9: 54-70 (Top research highlight) (PMC2808267).

Yang, W.*, Cai, Q.*, Lui, V. W. Y., Everley, P. A., Kim, J., Bhola, N., Quesnelle, K. M., Zetter, B. R., Steen, H., Freeman, M. R., Grandis, J. R. (2010) Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J. Proteome Res. 9: 3073-3082 (*co-first author) (PMC3149825)

Di Vizio, D., Kim, J., Hager, M. H., Morello, M., Yang, W., Lafargue, C. J., True, L. D., Rubin, M. A., Adam, R. M., Beroukhim, R., Demichelis, F., Freeman, M. R. (2009) Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69: 5601-5609. (PMC2853876)

Adam, R. M., Yang, W., Di Vizio, D., Mukhopadhyay, N. K., Steen, H. Rapid preparation of nuclei-depleted detergent-resistant membrane fractions suitable for proteomics analysis. BMC Cell Biol. 9: 30. (PMC2440737)

Yang, W., Steen, H., Freeman, M.R. (2008) Proteomic approaches to the analysis of multiprotein signaling complexes. Proteomics 8: 832-851. (Cover art)

He, S.Z., Wang, Q.S., He, J.T., Pu, H., Yang W., Ji, J.G. (2006) Proteomic analysis and comparison of the biopsy and autopsy specimen of human brain temporal lobe. Proteomics 6: 4987-4996.

Yang, W., Liu, P., Liu, Y.S., Wang, Q.S., Tong, Y.P., Ji, J.G. (2006) Proteomic analysis of rat pheochromocytoma PC12 cells. Proteomics 6: 2982-2990.

Chen, T., Wang, Q., Cui, J., Yang, W., Shi, Q., Hua, Z., Ji, J., Shen, P. (2005) Induction of apoptosis in mouse liver by microcystin-LR: a combined transcriptomic, proteomic, and simulation strategy. Mol. Cell. Proteomics 4: 958-974. (Cover art)

Zhou, B.*, Yang, W.*, Ji, J.G. and Ru, B.G. (2004) Differential display proteome analysis of PC-12 cells transiently transfected with metallothionein-3 gene. J. Proteome Res. 3: 126-131. (*co-first author)

Zhou, B., Yang, W., Zhang, J.H., Tong, Y.P., Zhao, R., Ji J.G. and Ru, B.G. (2003) Comparative proteome analysis of human brain occipital lobes during the course of aging. Chem. J. Chin. Univ. -Chin. 24: 2202-2207. (In Chinese)

Zhou, B., Yang, W., Ji, J.G., and Ru, B.G. (2003) Differential protein expression induced by transient transfection of metallothionein-3 gene in SH-SY5Y neuroblastoma cell line. Acta Biochim. Biophys. Sin. 35: 522-528.

Haiyen Zhau, PhD

*Zhau HYE, Chang S-M, Chen B-Q, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK.
(1996) Androgen-repressed phenotype in human prostate cancer. Proc Nat’l Acad of Sci. 93:15152-7. PMCID:PMC26372

Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, Chung LWK, *Zhau HYE. (2006)
Prostate cancer metastasis: Role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate. 66:1664-1673. PMID:16902972

Huang WC, Wu D, Xie Z, Zhau HYE, Nomura T, Zayzafoon M, Pohl J, Hsieh CL, Weitzmann MN, Chung LWK. (2006) β2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res. 66:9108-16. PMID:16982753

Huang WC, Havel JJ, Zhau HYE, Qian WP, Lue HW, Chu CY, Nomura T, Chung LWK. (2008) 2-Microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clin Cancer Res. 14:5341-7. PMCID: PMCID:PMC26372

Odero-Marah VA, Wang R, Chu G, Xu J, Shi C, Marshall FF, Zhau HYE, Chung LWK. (2008) Receptor Activator of NF-κB Ligand (RANKL) Expression is Associated with Epithelial to Mesenchymal Transition in Human Prostate Cancer Cells. Cell Research 18:858-70. PMID:18645583

*Zhau HYE, Odero-Marah VA, Lue H-W, Nomura T, Wang R, Chu G, Liu Z-R, Zhou BP, Huang WC, Chung LWK. (2008) Epithelial to Mesenchymal Transition (EMT) in Human Prostate Cancer: Lessons Learned from ARCaP Model. Clinical and Experimental Metastasis. 25:601-10, 2008. Learned from ARCaP Model. Clinical and Experimental Metastasis 25:601-10. PMCID:PMC3050737

Zhang SM, Zhau HYE, Osunkoya AO, Iqbal S, XJ Yang XJ, Fan SQ, Chen ZJ, Wang RX, Fray F.
Marshall FF, Leland LWK, Wu DQ. (2010) Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Molecular Cancer. 9:9. PMCID:PMC2820018

Huang W-C, Zhau HYE, Chung LWK. (2010) Androgen receptor survival signaling is blocked by anti- 2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. JBC. 285(11): 7947-56. PMCID:PMC2832945

Zhang S, Wang X, Osunkoya AO, Iqbal S, Chen Z, Muller S, Chen Z, Josson S, Coleman IM, Nelson PS, Wang YA, Wang RX, Shin DM, Marshall FF, Kucuk O, Chung LW, *Zhau HYE, Wu D. (2011) EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene. 30(50):4941-4952. PMCID:3165108

Zhau HYE, He H, Wang CY, Zayzafoon M, Morrissey CM, Vessella RL, Marshall FF, Chung LWK, Wang R. (2011) Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells. Clin Cancer Res. 17(8):2159-69. PMCID:PMC3085118

Lue HW, Yang X, Wang R, Qian W, Xu RZ, Lyles R, Osunkoya AO, Zhou BP, Vessella RL, Zayzafoon M, Liu ZR, *Zhau HYE, Chung LWK. (2011) LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PLoS One. 6(11):e27720. PMCID:PMC3218022

Hu P, Chu GC, Zhu G, Yang H, Luthringer D, Prins G, Habib F, Wang Y, Wang R, Chung LWK, *Zhau HYE. (2011) Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS One 6 (12):e28670. PMCID:PMC3244400

Zhang S, Wang X, Iqbal S, Wang Y, Osunkoya AO, Chen Z, Chen Z, Shin DM, Yuan H, Wang YA, Zhau HYE, Chung LW, Ritenour C, Kucuk O, Wu D. (2013) Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. J Biol Chem. 288(3): 1469-1479. PMCID:PMC3548460

*Zhau HYE, Li Q, Chung LWK. (2013) Interracial differences in prostate cancer progression among patients from the United States, China and Japan. Asian J Androl Jul 22. doi:10.1038/aja.2013.86. [Epub ahead of print] NIHMSID: 516945

Hu P, Chung LWK, Berel D, Frierson HF, Yang H, Liu C, Wang R, Li Q, Rogatko A, *Zhau HYE. (2013) Convergent RANK- and c-Met-Mediated Signaling Components Predict Survival of Patients with Prostate Cancer: An Interracial Comparative Study. PLoS One. 8(9):e73081. PMCID:PMC3774681

Android app on Google Play